Strategic use of biosimilars in cancer care provides an opportunity for more value as these drugs frequently cost less than...
As oncology costs continue to escalate and treatment decisions are more complex than ever, Eviti Connect empowers providers and payers...
Many factors go into making an informed treatment decision. Eviti Advisor supports physicians in the treatment decision process using a...
Oncology has a lot on its plate. As cancer care is welcoming a bounty of new treatments, it is absorbing...
With many new emerging technologies in healthcare, we look at how these technologies impact patient-centric care. Learn more from NantHealth...
The 2020 San Antonio Breast Cancer Symposium (SABCS) was held from December 8 to December 12, 2020. During the virtual...
Navigating the unknowns of a new diagnosis and treatment plan can be stressful – that’s where Eviti comes in. With...
Dr. William Flood, Chief Medical Officer for Eviti at NantHealth, discusses new significant findings from Eviti Connect, presented at the...
The challenges of last year tested all of us. Whether you were like me and adjusting to homeschooling your children...
Ensuring that everyone has access to healthcare is essential. Access should be coupled with an emphasis on screening and prevention...
The cost of oncology-focused drugs in the U.S. has now exceeded $56 billion and the median annual expense of a new cancer...
NantHealth’s study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to...
